US biopolymers firm Metabolix has announced its latest financial results for 2014. The company remains short of cash and in danger of being delisted by the US Nasdaq stock exchange. Losses in the year ending 31 December 2014 were lower than in 2013, as the company reorganised its operations with its near-term business goals in mind. Total losses in 2014 were $29.5 million (?27.2 million), compared to $30.5 million. Further efficiencies can be expected in 2015, as the company shed its European operation, Metabolix GmbH (see Bioplastics World 2.20); though some of these will be offset by the company’s scale-up of production facilities for its PHA bioplastics.
展开▼
